

## Items Supported by the CCF Medical Assistance Programmes

(a) Drugs Supported by the First Phase Programme

(b) Drugs Supported by the Programme “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”

(c) Implantable Medical Devices Supported by the Programme “Subsidy for Eligible Patients of Hospital Authority to Purchase Specified Implantable Medical Devices for Interventional Procedures”

### (a) Drugs Supported by the First Phase Programme

The following specific self-financed cancer drugs are supported by the first phase programme:

Item	Drug	Types of diseases	Clinical indications
1	Abemaciclib <sup>#</sup>	Breast cancer	For treatment of HR+ve HER2-ve locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine therapy
2a	Abiraterone <sup>#</sup>	Prostate cancer	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen
2b			For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel
3	Alectinib <sup>#</sup>	Lung cancer	For the treatment of patients with ALK+ve, metastatic non-small cell lung cancer (NSCLC) who have progressed on Crizotinib and intolerant to Ceritinib, or who have CNS-progression after Crizotinib
4	Atezolizumab	Lung cancer	For EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy
5	Axitinib <sup>#</sup>	Renal cell carcinoma	For patients with advanced renal cell carcinoma (RCC), whose disease has progressed on or after first-line treatment
6	Bendamustine	Leukaemia	Treatment of Chronic Lymphocytic Leukaemia (CLL) in patients who are unable to tolerate Fludarabine-based chemotherapy OR are refractory to Fludarabine i.e. not responded to Fludarabine or relapsed within 12 months of treatment

Item	Drug	Types of diseases	Clinical indications
7a	Bevacizumab	Colorectal cancer	First line treatment of RAS mutant metastatic colorectal cancer in combination with chemotherapy in patients indicated for intensive treatment OR First line treatment of RAS wild type metastatic colorectal cancer in combination with chemotherapy in patients indicated for intensive treatment who are unsuitable for or intolerant to Cetuximab / Panitumumab
7b		Epithelial ovarian / fallopian tube / primary peritoneal cancer	With carboplatin and paclitaxel for front-line advanced epithelial ovarian / fallopian tube / primary peritoneal cancer
8a	Brentuximab Vedotin	Lymphoma	For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (RR/HL): (i) following autologous stem cell transplant (ASCT), or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option
8b			For the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma
8c			For the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy
9	Brigatinib <sup>#</sup>	Lung cancer	For the treatment of patients with ALK+ve, metastatic non-small cell lung cancer (NSCLC) who have progressed on Crizotinib and intolerant to Ceritinib, or who have central nervous system (CNS)-progression after Crizotinib
10	Ceritinib <sup>#</sup>	Lung cancer	For adult patients with ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib
11	Dabrafenib <sup>#</sup>	Skin cancer	Combination of dabrafenib and trametinib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
12	Trametinib <sup>#</sup>		
13	Durvalumab	Lung cancer	For unresectable, stage III non-small cell lung cancer (NSCLC) with at least 1% of tumour cells expressing PD-L1, whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy

Item	Drug	Types of diseases	Clinical indications
14a	Enzalutamide <sup>#</sup>	Prostate cancer	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen
14b			For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel
15	Everolimus <sup>#</sup>	Breast cancer	For HR+ve HER2-ve advanced breast cancer, in combination with Exemestane, in postmenopausal women with bone-only disease after recurrence or progression following a non-steroidal aromatase inhibitor
16	Inotuzumab Ozogamicin	Leukaemia	As monotherapy for the treatment of transplant-eligible adult patients with relapsed or refractory CD22-positive B cell acute lymphoblastic leukaemia (ALL) that is either Philadelphia chromosome negative, or Philadelphia chromosome positive failing at least 1 prior TKI treatment
17	Ixazomib <sup>#</sup>	Multiple myeloma	In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy
18	Lenalidomide <sup>#</sup>		
19	Lapatinib	Breast cancer	HER2+ve advanced breast cancer with prior therapy including an anthracycline, a taxane, and Trastuzumab
20	Lenvatinib <sup>#</sup>	Liver cancer	For first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
21a	Nivolumab	Skin cancer	As monotherapy for BRAF V600 wild-type unresectable or metastatic melanoma
21b			For adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
21c		Lung cancer	For EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy
22	Obinutuzumab	Leukaemia	In combination with Chlorambucil for treatment of previously untreated chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy

Item	Drug	Types of diseases	Clinical indications
23	Olaparib <sup>#^</sup>	Epithelial ovarian / fallopian tube / primary peritoneal cancer	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response after first-line platinum-based chemotherapy
24a	Osimertinib <sup>#</sup>	Lung cancer	For the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation positive non-small cell lung cancer (NSCLC) who has progressed after previous treatment with an EGFR TKI
24b		Lung cancer	First line treatment of adult patients with EGFR mutation +ve non-small cell lung cancer (NSCLC) with CNS metastases <sup>^</sup>
25	Palbociclib <sup>#</sup>	Breast cancer	For treatment of HR+ve HER2-ve locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine therapy
26	Pazopanib	Renal cell carcinoma	First line treatment for advanced renal cell carcinoma
27	Pegylated liposomal Doxorubicin	Ovarian cancer	Second-line of platinum refractory or subsequent treatment of platinum resistant advanced ovarian cancer
28a	Pembrolizumab	Lung cancer	For first-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score $\geq 50\%$ ) with no EGFR or ALK genomic tumor aberrations
28b		Bladder cancer	Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy <sup>^</sup>
29	Pertuzumab	Breast cancer	In combination with trastuzumab and docetaxel (Taxane) in HER2+ve metastatic or locally recurrent unresectable breast cancer patients with no prior anti-HER2 or chemotherapy for their metastatic disease
30	Ribociclib <sup>#</sup>	Breast cancer	For treatment of HR+ve HER2-ve locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine therapy
31a	Sunitinib	Renal cell	First line treatment for advanced renal cell carcinoma

Item	Drug	Types of diseases	Clinical indications
		carcinoma	
31b		Gastrointestinal tumour	Unresectable or metastatic gastrointestinal stromal tumour after failure or intolerance to Imatinib
32	Trastuzumab	Gastric carcinoma	Combined with Cisplatin & Capecitabine or 5FU for HER2 overexpressed metastatic gastric disease (IHC2+ and confirmatory FISH+ result, or IHC3+) in treatment-naive patients for their metastatic disease
33	Trastuzumab emtansine (T-DM1)	Breast cancer	As monotherapy for HER2+ve metastatic breast cancer with prior Trastuzumab and/or taxane therapy for their metastatic disease
34	Vemurafenib	Skin cancer	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma

^ With effect from 22 May 2021.

# The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacy. For details, please refer to the [\[Information Sheet\]](#).

**Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)**

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Haematology	Acute lymphoblastic leukaemia	Dasatinib, Ponatinib <sup>^</sup>	✓	
		Inotuzumab Ozogamicin		✓
	Acute myeloid leukaemia	Midostaurin <sup>#</sup>	✓	
	Chronic immune thrombocytopenia	Eltrombopag	✓	
	Chronic lymphocytic leukaemia	Ibrutinib <sup>#</sup> , Rituximab	✓	

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
		Bendamustine, Obinutuzumab		✓
	Chronic myeloid leukaemia	Dasatinib, Nilotinib, Ponatinib <sup>^</sup>	✓	
	Follicular lymphoma	Obinutuzumab, Rituximab	✓	
	Mantle cell lymphoma	Ibrutinib <sup>#</sup>	✓	
	Multiple myeloma	Bortezomib, Carfilzomib, Lenalidomide <sup>**</sup> , Pomalidomide <sup>#^</sup>	✓	
		Ixazomib <sup>#</sup> & Lenalidomide <sup>**</sup>		✓
	Multiple myeloma / Non-Hodgkin's lymphoma	Plerixafor	✓	
	Myelodysplastic syndromes / chronic myelomonocytic leukaemia / acute myeloid leukaemia	Azacitidine	✓	
	Myelofibrosis-related splenomegaly or symptoms	Ruxolitinib <sup>#</sup>	✓	
	Paroxysmal nocturnal haemoglobinuria	Eculizumab	✓	
	Severe aplastic anaemia	Eltrombopag <sup>#^</sup>	✓	
	CD30+ Hodgkin lymphoma / Systemic anaplastic large cell lymphoma / CD30+ cutaneous T-cell lymphoma	Brentuximab Vedotin		✓
Respiratory Medicine	Idiopathic pulmonary fibrosis	Nintedanib (Ofev) <sup>#</sup>	✓	
	Severe persistent confirmed allergic IgE mediated asthma	Omalizumab	✓	

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Severe refractory eosinophilic asthma	Mepolizumab, Benralizumab	✓	
Rheumatology	Systemic juvenile idiopathic arthritis	Tocilizumab	✓	
	Ankylosing spondylitis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab	✓	
	Juvenile idiopathic arthritis	Adalimumab, Etanercept, Tocilizumab	✓	
	Psoriatic arthritis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab, Tofacitinib^ Ustekinumab	✓	
	Rheumatoid arthritis	Abatacept, Adalimumab, Baricitinib, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Sarilumab, Tocilizumab, Tofacitinib	✓	
	Refractory rheumatoid arthritis	Rituximab	✓	
	Refractory giant cell arteritis	Tocilizumab	✓	
	Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis	Rituximab	✓	

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Systemic lupus erythematosus (SLE)	Belimumab	✓	
Nephrology	Autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc)	✓	
Neurology	Relapsing remitting multiple sclerosis	Natalizumab	✓	
Oncology	Bladder cancer	Pembrolizumab <sup>^</sup>		✓
	Breast cancer	Pertuzumab <sup>*^</sup> and Trastuzumab, Trastuzumab emtansine <sup>*^</sup>	✓	
		Abemaciclib <sup>#</sup> , Everolimus <sup>#</sup> , Lapatinib, Palbociclib <sup>#</sup> , Pertuzumab <sup>*</sup> , Ribociclib <sup>#</sup> , Trastuzumab emtansine <sup>*</sup>		✓
	Colorectal cancer	Cetuximab, Panitumumab	✓	
		Bevacizumab		✓
	Gastric carcinoma	Trastuzumab		✓
	Gastrointestinal tumour	Sunitinib		✓
	Gastrointestinal stromal tumour	Imatinib	✓	
	Recurrent high grade glioma	Temozolomide	✓	
	Liver cancer	Sorafenib	✓~	
		Lenvatinib <sup>#</sup>		✓
	Lung cancer	Ceritinib <sup>*#</sup> ,	✓	✓



Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
		Afatinib, Alectinib <sup>**</sup> , Crizotinib <sup>#</sup> , Gefitinib	✓	
		Alectinib <sup>**</sup> , Atezolizumab, Brigatinib <sup>#</sup> , Durvalumab, Nivolumab, Osimertinib <sup>#</sup> , Pembrolizumab		✓
	Malignant lymphoma	Rituximab	✓	
	Ovarian cancer	Pegylated liposomal Doxorubicin		✓
	Epithelial ovarian / fallopian tube / primary peritoneal cancer	Bevacizumab, Olaparib <sup>#^</sup>		✓
	Prostate cancer	Abiraterone <sup>#</sup> , Enzalutamide <sup>#</sup>		✓
	Renal cell carcinoma	Axitinib <sup>#</sup> , Sunitinib, Pazopanib		✓
	Skin cancer	Dabrafenib <sup>#</sup> and Trametinib <sup>#</sup> , Nivolumab, Vemurafenib		✓
Gastroenterology	Severe ulcerative colitis	Infliximab, Vedolizumab	✓	
Ophthalmology	Non-infectious intermediate, posterior and panuveitis	Adalimumab	✓	
	Paediatric chronic non-infectious anterior uveitis	Adalimumab	✓	
Endocrinology	Dwarfism	Growth Hormone	✓	

Types of Diseases	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Dermatology	Severe psoriasis	Adalimumab, Etanercept, Guselkumab, Infliximab, Risankizumab <sup>^</sup> , Secukinumab, Ustekinumab	✓	
Others	Chronic granulomatous disease	Interferon	✓	
	Cryopyrin-associated periodic syndromes	Canakinumab	✓	

Remarks:

<sup>^</sup> With effect from 22 May 2021.

<sup>\*</sup> The designated clinical indications of the same drug supported by different funds are different. Please consult your case doctor for details.

<sup>~</sup> Sorafenib is repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 29 December 2020. New applications and renewal applications approved on or after the effective date will be subsidized by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.

<sup>#</sup> The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

**(b) Drugs Supported by the Programme “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”**

Item	Drug	Clinical indications
1	Dinutuximab Beta	Treatment of high-risk or relapse/refractory neuroblastoma
2	Eculizumab	Atypical haemolytic uraemic syndrome
3	Nusinersen	Infantile Onset Spinal Muscular Atrophy (SMA) / Childhood Onset Spinal Muscular Atrophy (SMA)
4	Tafamidis	For the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment
5	Tisagenlecleucel	Paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse / Adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

**(c) Implantable Medical Devices Supported by the Programme “Subsidy for Eligible Patients of Hospital Authority to Purchase Specified Implantable Medical Devices for Interventional Procedures”**

1. Transcatheter Aortic Valve Implantation (TAVI)
2. MitraClip System
3. Percutaneous Pulmonary Valve Implantation (PPVI)
4. Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)
5. Impella
6. Valve-in-Valve Transcatheter Aortic Valve Implantation (VIV – TAVI)

Patients who have financial difficulties may apply for assistance from the CCF. Eligible applicants may be given full or partial subsidy of the cost, depending on their financial situation.

For details of the Samaritan Fund, please refer to the [Samaritan Fund](#) web page in the Hospital Authority Website.